PMID- 21481270
OWN - NLM
STAT- MEDLINE
DCOM- 20110610
LR  - 20211020
IS  - 1756-9966 (Electronic)
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 30
IP  - 1
DP  - 2011 Apr 11
TI  - Evaluation of HER2 and p53 expression in predicting response to docetaxel-based 
      first-line chemotherapy in advanced breast cancer.
PG  - 38
LID - 10.1186/1756-9966-30-38 [doi]
AB  - BACKGROUND: The human epidermal growth factor receptor 2 (HER2) and p53 pathways 
      may be involved in chemotherapy sensitivity and/or resistance. We explore the 
      value of HER2 and p53 status to foretell docetaxel sensitivity in advanced breast 
      cancer. METHODS: HER2 and p53 expression was analysed in 36 (median age 55 yrs; 
      range 37-87) metastatic breast cancer patients receiving docetaxel-based 
      first-line chemotherapy. HER2 was determined by immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH), p53 was tested by IHC. We correlate 
      the expression of study parameters with pathologic parameters, RECIST response 
      and survival. The standard cut-off value of 2 was used to determine HER2 
      overexpression while p53 mean expression level was used to divide low/high 
      expressors tumors. RESULTS: Median time to progression and overall survival were 
      9 (range 2-54) and 20 (range 3-101) months. Overall response rate was 41.6%. Nine 
      cases showed HER2 overexpression. HER2 was more frequently overexpressed in less 
      differentiated (p=0.05) and higher stage (p=0.003) disease. Mean FISH-HER2 values 
      were significantly higher in responder than in non-responder pts (8.53+/-10.21 vs 
      2.50+/-4.12, p=0.027). Moreover, HER2 overexpression correlates with treatment 
      response at cross-tabulation analysis (p=0.046). p53 expression was only 
      associated with higher stage disease (p=0.02) but lack of any significant 
      association with HER status or docetaxel response. No significant relation with 
      survival was observed for any parameter. CONCLUSION: Our data seem to indicate 
      that FISH-determined HER2 status but not p53 is associated with docetaxel 
      sensitivity in metastatic breast cancer.
FAU - Camerini, Andrea
AU  - Camerini A
AD  - Oncology Department, Medical Oncology Division, AUSL12 di Viareggio and Istituto 
      Toscano Tumori-Versilia Hospital, Lido di Camaiore, Italy. 
      andreacamerini@katamail.com
FAU - Donati, Sara
AU  - Donati S
FAU - Viacava, Paolo
AU  - Viacava P
FAU - Siclari, Olimpia
AU  - Siclari O
FAU - Puccetti, Cheti
AU  - Puccetti C
FAU - Tartarelli, Gianna
AU  - Tartarelli G
FAU - Valsuani, Chiara
AU  - Valsuani C
FAU - De Luca, Filomena
AU  - De Luca F
FAU - Martini, Leonardo
AU  - Martini L
FAU - Cavazzana, Andrea
AU  - Cavazzana A
FAU - Amoroso, Domenico
AU  - Amoroso D
LA  - eng
PT  - Journal Article
DEP - 20110411
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Antineoplastic Agents)
RN  - 0 (TP53 protein, human)
RN  - 0 (Taxoids)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 15H5577CQD (Docetaxel)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/enzymology/*metabolism/surgery
MH  - Carcinoma, Ductal, Breast/drug therapy/enzymology/metabolism/surgery
MH  - Combined Modality Therapy
MH  - Docetaxel
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Receptor, ErbB-2/*biosynthesis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Taxoids/*therapeutic use
MH  - Tumor Suppressor Protein p53/*biosynthesis
PMC - PMC3080331
EDAT- 2011/04/13 06:00
MHDA- 2011/06/11 06:00
PMCR- 2011/04/11
CRDT- 2011/04/13 06:00
PHST- 2010/11/30 00:00 [received]
PHST- 2011/04/11 00:00 [accepted]
PHST- 2011/04/13 06:00 [entrez]
PHST- 2011/04/13 06:00 [pubmed]
PHST- 2011/06/11 06:00 [medline]
PHST- 2011/04/11 00:00 [pmc-release]
AID - 1756-9966-30-38 [pii]
AID - 10.1186/1756-9966-30-38 [doi]
PST - epublish
SO  - J Exp Clin Cancer Res. 2011 Apr 11;30(1):38. doi: 10.1186/1756-9966-30-38.